Journal Report

JOURNAL OF CHEMOTHERAPY

Download PDF
Journal Information
Journal Title
JOURNAL OF CHEMOTHERAPY
Publisher
TAYLOR & FRANCIS LTD
ISSN
1120-009X
E-ISSN
1973-9478
Database
Clarivate
Domain
Health Sciences, Life Sciences, Physical Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Time-dependent indirect comparison of enfortumab vedotin plus pembrolizumab and disitamab vedotin plus toripalimab in advanced urothelial carcinoma
Hiroki Tanaka, Hiroshi Fukushima, Wei Chen et al.
2026-10-29 Pages 1-5
DOI: 10.1080/1120009x.2026.2751380
Integrative topological and longitudinal transcriptomic analyses identify a 14-gene interferon-stimulated module associated with acquired sunitinib resistance in clear cell renal cell carcinoma
Wenhao Chu, Fuhao Wang, Liangkuan Bi et al.
2026-10-22 Pages 1-11
DOI: 10.1080/1120009x.2026.2751379
Emerging roles of long non-coding RNA CASC2 in tumor chemoresistance – a review
Lingyun Zhou, Jintao He, Wenbing Huang et al.
2026-10-4 Pages 1-16
DOI: 10.1080/1120009x.2026.2739728
Hepatic arterial infusion chemotherapy plus lenvatinib with or without PD-1 inhibition for unresectable hepatocellular carcinoma: a retrospective cohort study
Haidong Yu, Cunkai Ma, Cairang Yangdan et al.
2026-9-30 Pages 1-16
DOI: 10.1080/1120009x.2026.2737018
Longitudinal acquisition and infection risk associated with multidrug-resistant organisms and <i>Candida</i> colonization in intensive care unit patients
Ülkü Altoparlak, Hatice Erdoğan, Mine Çelik et al.
2026-9-12 Pages 1-15
DOI: 10.1080/1120009x.2026.2732415
Circular RNAs: key regulators and mechanistic insights in breast cancer drug resistance
Yaxuan Zhao, Xiaoyong Lei, Xiaoyan Yang
2026-9-10 Pages 1-23
DOI: 10.1080/1120009x.2026.2729966
Tumor resistance to protein kinase inhibitors
Mridul Singh Sengar, Ajita Paliwal, Niranjan Kaushik et al.
2026-9-10 Pages 1-15
DOI: 10.1080/1120009x.2026.2728432
First-line therapy and maintenance outcomes in Chinese patients with marginal zone lymphoma: a multicenter retrospective analysis with prognostic implications for chemotherapy decision-making
Yanyan Qiu, Yimei Weng, Xinyuan Su et al.
2026-9-5 Pages 1-9
DOI: 10.1080/1120009x.2026.2727267
The epigenetic regulator ALKBH5 facilitates the early adaptation of hepatocellular carcinoma cells to sorafenib treatment
Meng Li, Jiayu Wang, Shuai Fang et al.
2026-9-3 Pages 1-17
DOI: 10.1080/1120009x.2026.2722741
Targeting glutaminase (GLS) to suppress CXCL8 secretion and sensitize esophageal squamous cell carcinoma to immunotherapy
Xiu Zhang, Jiang Chao, Zhuqing Ji et al.
2026-9-1 Pages 1-17
DOI: 10.1080/1120009x.2026.2722740
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: October 31, 2026 16:07